OBJECTIVE: The objective of this study is to determine the breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity (ADCC) in HIV controllers and HIV progressors with a view to design globally relevant HIV vaccines. DESIGN: The breadth of ADCC towards four major HIV-1 Env subtypes was measured in vitro for 11 HIV controllers and 11 HIV progressors. METHODS: Plasma from 11 HIV controllers (including long-term slow progressors, viremic controllers, elite controller and posttreatment controller) and 11 HIV progressors, mostly infected with HIV-1 subtype B, was analysed for ADCC responses. ADCC assays were performed against 10 HIV-1 gp120 and 8 gp140 proteins from four major HIV-1 subtypes (A, B, C and E) and 3 glycosylation-mutant gp140 proteins. RESULTS: ADCC-mediated natural killer cell activation was significantly broader (P = 0.02) and of higher magnitude (P < 0.001) in HIV controllers than in HIV progressors. HIV controllers also showed significantly higher magnitude of ADCC-mediated killing of Env-coated target cells than HIV progressors to both HIV-1 subtype B and the heterologous subtype E gp140 (P = 0.001). We found good ADCC reactivity to subtype B and E Envs, less cross-reactivity to subtype A and minimal cross-reactivity to subtype C Envs. Glycosylation-dependent ADCC epitopes comprise a significant proportion of the total Env-specific ADCC response, as evident from the reduction in ADCC to nonglycosylated form of HIV-1 gp140 (P = 0.004). CONCLUSION: HIV controllers have robust ADCC responses that recognize a broad range of HIV-1 Env. Glycosylation of Env was found to be important for recognition of ADCC epitopes. Identifying conserved ADCC epitopes will assist in designing globally relevant ADCC-based HIV vaccines.
OBJECTIVE: The objective of this study is to determine the breadth of HIV-1Env-specific antibody-dependent cellular cytotoxicity (ADCC) in HIV controllers and HIV progressors with a view to design globally relevant HIV vaccines. DESIGN: The breadth of ADCC towards four major HIV-1Env subtypes was measured in vitro for 11 HIV controllers and 11 HIV progressors. METHODS: Plasma from 11 HIV controllers (including long-term slow progressors, viremic controllers, elite controller and posttreatment controller) and 11 HIV progressors, mostly infected with HIV-1 subtype B, was analysed for ADCC responses. ADCC assays were performed against 10 HIV-1gp120 and 8 gp140 proteins from four major HIV-1 subtypes (A, B, C and E) and 3 glycosylation-mutant gp140 proteins. RESULTS: ADCC-mediated natural killer cell activation was significantly broader (P = 0.02) and of higher magnitude (P < 0.001) in HIV controllers than in HIV progressors. HIV controllers also showed significantly higher magnitude of ADCC-mediated killing of Env-coated target cells than HIV progressors to both HIV-1 subtype B and the heterologous subtype E gp140 (P = 0.001). We found good ADCC reactivity to subtype B and E Envs, less cross-reactivity to subtype A and minimal cross-reactivity to subtype C Envs. Glycosylation-dependent ADCC epitopes comprise a significant proportion of the total Env-specific ADCC response, as evident from the reduction in ADCC to nonglycosylated form of HIV-1 gp140 (P = 0.004). CONCLUSION: HIV controllers have robust ADCC responses that recognize a broad range of HIV-1Env. Glycosylation of Env was found to be important for recognition of ADCC epitopes. Identifying conserved ADCC epitopes will assist in designing globally relevant ADCC-based HIV vaccines.
Authors: Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov Journal: J Virol Date: 2017-08-24 Impact factor: 5.103
Authors: Saheli Sadanand; Jishnu Das; Amy W Chung; Matthew K Schoen; Sophie Lane; Todd J Suscovich; Hendrik Streeck; Davey M Smith; Susan J Little; Douglas A Lauffenburger; Douglas D Richman; Galit Alter Journal: AIDS Date: 2018-02-20 Impact factor: 4.177
Authors: Marie Borggren; Sanne Skov Jensen; Leo Heyndrickx; Angelica A Palm; Jan Gerstoft; Gitte Kronborg; Bo Langhoff Hønge; Sanne Jespersen; Zacarias José da Silva; Ingrid Karlsson; Anders Fomsgaard Journal: AIDS Res Hum Retroviruses Date: 2016-01-07 Impact factor: 2.205
Authors: Paul Spearman; Georgia D Tomaras; David C Montefiori; Ying Huang; Marnie L Elizaga; Guido Ferrari; S Munir Alam; Abby Isaacs; Hasan Ahmed; John Hural; M Juliana McElrath; Laissa Ouedraogo; Michael Pensiero; Chris Butler; Spyros A Kalams; Edgar Turner Overton; Susan W Barnett Journal: J Infect Dis Date: 2019-05-05 Impact factor: 5.226
Authors: Raymond A Alvarez; Ana M Maestre; Kenneth Law; Natasha D Durham; Maria Ines Barria; Akiko Ishii-Watabe; Minoru Tada; Manav Kapoor; Mathew T Hotta; Gabriela Rodriguez-Caprio; Daniel S Fierer; Ana Fernandez-Sesma; Viviana Simon; Benjamin K Chen Journal: JCI Insight Date: 2017-02-23
Authors: Evan D Rossignol; Anne-Sophie Dugast; Hacheming Compere; Christopher A Cottrell; Jeffrey Copps; Shu Lin; Deniz Cizmeci; Michael S Seaman; Margaret E Ackerman; Andrew B Ward; Galit Alter; Boris Julg Journal: Cell Rep Date: 2021-05-25 Impact factor: 9.423
Authors: Katherine L Williams; Valerie Cortez; Adam S Dingens; Johannes S Gach; Stephanie Rainwater; Julie F Weis; Xuemin Chen; Paul Spearman; Donald N Forthal; Julie Overbaugh Journal: EBioMedicine Date: 2015-10 Impact factor: 8.143